Palvella Therapeutics, Inc. (PVLA) vs Xencor, Inc. (XNCR)

Palvella Therapeutics, Inc. and Xencor, Inc. are both Biotechnology companies. Palvella Therapeutics, Inc. and Xencor, Inc. are of similar size ($1.8B and $1.8B). Palvella Therapeutics, Inc. grew revenue faster over the last twelve months: 146.7% against −28.6%. Palvella Therapeutics, Inc. has the higher net margin (0.00% vs −155.6%) and the higher return on invested capital (0.00% vs −288.7%). Across the 16 metrics below, Palvella Therapeutics, Inc. leads on 10 and Xencor, Inc. on 6.

Valuation

Metric PVLA XNCR Biotechnology median
P/E n/m n/m 8.50
P/S 41.55 16.58 9.71
P/B 7.96 3.46 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 35.55 13.38 9.21
Earnings yield (4.01%) (9.46%) (33.15%)
Free cash flow yield (1.86%) (12.02%) (25.50%)

Profitability

Metric PVLA XNCR Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin 0.00% (205.84%) 0.00%
Net margin 0.00% (155.59%) 0.00%
Free cash flow margin 0.00% (198.42%) 0.00%
Return on equity (46.63%) (29.07%) (56.36%)
Return on assets (37.70%) (20.36%) (48.04%)
Return on invested capital 0.00% (288.71%) 0.00%

Growth

Metric PVLA XNCR Biotechnology median
Revenue growth (TTM) 146.67% (28.56%) 6.02%
EPS growth (last fiscal year) 52.62% 65.36% 30.26%
Revenue growth, 5-year CAGR 8.03% 0.47% 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric PVLA XNCR Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 21.18 6.39 4.72
Net debt to EBITDA 1.50 2.51 0.96

Dividend

Metric PVLA XNCR Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric PVLA XNCR Biotechnology median
Market cap 1.83b 1.78b 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack